Azilpres 40 mg (Tablet)

Indications

• Treatment of hypertension
• Lowering blood pressure
• Reducing risk of cardiovascular events
• Can be used alone or in combination with other antihypertensive agents

Pharmacology

• Blocks angiotensin II effects
• Reduces vasoconstriction
• Stimulates release of aldosterone
• Cardiac stimulation
• Renal reabsorption of sodium
• Inhibits ACE (kinase II)
• Selectively blocks AT1 receptor
• Does not affect bradykinin levels
• Does not bind to or block other receptors or ion channels
• Inhibits negative regulatory feedback of angiotensin II on renin secretion

Dosage & Administration

• Recommended adult dose: 80 mg orally once daily
• Starting dose of 40 mg for patients treated with high doses of diuretics
• Additional blood pressure reduction achievable by combining with other antihypertensive agents

Interaction

• No observed drug interactions with specified drugs
• Potential attenuation by non-steroidal anti-inflammatory drugs

Contraindications

• Contraindicated to co-administer Aliskiren with Azilsartan in patients with Diabetes

Side Effects

• Most common adverse reaction: diarrhea
• Other side effects: nausea, asthenia, fatigue, muscle spasm, dizziness, cough

Pregnancy & Lactation

• Pregnancy Category D
• Risk to fetus increases if administered during second or third trimesters
• Unknown excretion in human milk
• Consideration for discontinuation of nursing or drug

Precautions & Warnings

• Reduces fetal renal function and increases fetal and neonatal morbidity and death when used during 2nd and 3rd trimesters of pregnancy
• Symptomatic hypotension may occur in intravascularly volume-depleted patients
• Reported changes in renal function including renal failure in renal impaired patients

Use in Special Populations

• Pediatric use: Safety and effectiveness not established in patients under 18 years of age
• No dose adjustment necessary in elderly patients
• Dose adjustment not required in patients with mild-to-severe renal impairment or end-stage renal disease
• No dose adjustment necessary in mild or moderate hepatic impairment
• Not studied in patients with severe hepatic impairment

Overdose Effects

• Limited data available related to overdose in humans
• Supportive therapy should be instituted based on patient's clinical status
• Not dialyzable

Therapeutic Class

• Angiotensin-II receptor blocker

Storage Conditions

• Keep in a dry place away from light and heat
• Keep out of the reach of children

Related Brands

• Azilpres 80 mg (Tablet) - incepta-pharmaceuticals-ltd